MedTrace Logo

Kebele Elimination of Trachoma for Ocular Health

NCT03335072 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 320000

Last updated 2025-10-23

No results posted yet for this study

Summary

The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution.

Conditions

  • Trachoma

Interventions

DRUG

Azithromycin

Mass Drug Administration

Sponsors & Collaborators

Principal Investigators

  • Tom M Lietman, MD · University of California, San Francisco

  • Hadley Burroughs, MSPH · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2027-03-01
Completion
2028-03-01
FDA Drug
Yes

Countries

  • United States
  • Ethiopia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335072 on ClinicalTrials.gov